BTIG downgraded Exact Sciences (EXAS) to Neutral from Buy after Abbott (ABT) announced a deal to acquire Exact for $105 per share. The premium “caught us by surprise,” but the firm thinks this is “a great outcome” for Exact and “a good deal” for Abbott, the analyst tells investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS: